PTC THERAPEUTICS, INC. (PTCT)
PTC THERAPEUTICS, INC. (PTCT) from its SEC filings: 2025 revenue $1.7 billion (+114% vs the year before), net margin 40%, free cash flow $702.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $1.7 billion |
| Revenue growth | +114% |
| Net income | $683.0 million |
| Net margin | 39.5% |
| Free cash flow | $702.3 million |
| Diluted EPS | $7.78 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +102% |
| Cash | $1.0 billion |
| Long-term debt | $535.5 million |
| Share count, 1 year | +5% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.